Figures 4 a and b illustrates two MDMatrix Health products which have undergone rigorous in-vivo testing using oxalozone induced murine ear edema models. The type 4 delayed hypersensitivity resulting in ear edema involves formation of inflammatory molecules such as : COX and LOX enzymes, prostaglandins and leukotrines, MMP 2,9, ROS,Chemokines, andVEGF-A.
Reduction of inflammation helps stabilize the matrix addressing both acute and chronic symptoms. In Figure 4a the oral MDMatrix powder has the ability to lower inflammation by 73% compared to that of the powerful COX2 inhibition drug “Celecoxib”.
The MDMatrix cream delivers a high concentration of nutraceuticals to a defined area which enhances concentration of active ingredients. This permits a substantial improvement of inflammation reduction and matrix stabilization compared to oral blends. Figure 4b the MDMatrix cream achieves 83% reduction of inflammation compared to one of the most potent anti-inflammatory steroids, betamethasone (33 times more powerful than hydrocortisone). Compared with oral Celecoxib, MDMatrix reduces inflammation by 154%.
MDMatrix products also exhibit matrix stabilization synergy as illustrated in figure 4b. The combination of the oral MDMatrix powder and the MDMatrix Cream resulted in a 90% reduction of inflammation compared to the topical steroid and a 168% reduction compared to Celecoxib.
* These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure or prevent any disease.